Partial
Partially Aligned
Patient Risk:
Medium
Summary
Some claims match the provided label indications/clinical-study lipid and CV-risk outcomes, but multiple dosing/administration, monitoring/targets, and population-specific CV-prevention claims are not supported by the supplied label excerpts and several are overbroad or insufficiently anchored.
Category Scores
Accurate Statements
Rosuvastatin 20 mg is a statin medicine used to lower cholesterol.
Supported by lipid-lowering indications and hypercholesterolemia trial effects in the provided excerpts (1 INDICATIONS AND USAGE; 14 CLINICAL STUDIES).
Rosuvastatin 20 mg reduces cardiovascular risk.
Supported by indication to reduce risk of major adverse cardiovascular events (1 INDICATIONS AND USAGE).
Rosuvastatin is prescribed to treat high cholesterol (hyperlipidemia).
Supported by adjunct to diet to reduce LDL-C in adults with hypercholesterolemia (1 INDICATIONS AND USAGE).
Rosuvastatin 20 mg is used to prevent events such as heart attack and stroke in people at increased risk.
Supported by reduction in major CV events including nonfatal myocardial infarction and nonfatal stroke in the provided CV endpoint study description (1 INDICATIONS AND USAGE; 14 CLINICAL STUDIES).
Clinicians use rosuvastatin to lower LDL-C.
Supported by adjunct indication to reduce LDL-C (1 INDICATIONS AND USAGE) and LDL-C reductions in studies (14 CLINICAL STUDIES).
Rosuvastatin can lower triglycerides in some patients.
Supported by labeled indication for hypertriglyceridemia and TG-lowering effects in studies (1 INDICATIONS AND USAGE; 14 CLINICAL STUDIES).
Rosuvastatin can raise HDL-C modestly.
Supported by study statements/tables indicating increased HDL-C (14 CLINICAL STUDIES).
Rosuvastatin is generally taken once daily.
Supported by study dosing described as once daily (e.g., CRESTOR 20 mg once daily in JUPITER; and single daily dose regimens in provided study excerpts) (14 CLINICAL STUDIES).
Rosuvastatin can cause muscle-related symptoms.
Supported by patient counseling to promptly report unexplained muscle pain/tenderness/weakness and labeling describing myopathy/rhabdomyolysis (17 PATIENT COUNSELING INFORMATION).
Rosuvastatin can cause liver enzyme abnormalities.
Supported by patient counseling that CRESTOR may cause liver enzyme elevations (17 PATIENT COUNSELING INFORMATION).
Patients are advised to report unexplained muscle pain or weakness promptly.
Explicit in patient counseling (17 PATIENT COUNSELING INFORMATION).
Patients are advised to report dark urine promptly.
Explicit in patient counseling under hepatic dysfunction (17 PATIENT COUNSELING INFORMATION).
Unsupported Statements
Clinicians use rosuvastatin to lower other atherogenic lipids.
The provided label excerpt supports reductions in specific lipid parameters (e.g., non-HDL-C, ApoB, TG) but the claim is overbroad/unclear as to which labeled lipid endpoints it refers to (1 INDICATIONS AND USAGE; 14 CLINICAL STUDIES).
Rosuvastatin may be used for prevention of major cardiovascular events in people with established atherosclerotic disease.
The provided indication wording specifies adults at increased risk for CV events, without the explicit 'established atherosclerotic disease' population framing in the supplied excerpt (1 INDICATIONS AND USAGE).
Rosuvastatin may be used for prevention of major cardiovascular events in people with diabetes.
No diabetes-specific prevention population is supported by the provided indication excerpt (1 INDICATIONS AND USAGE).
Rosuvastatin may be used for prevention of major cardiovascular events in people with other conditions linked to increased cardiovascular risk.
The provided excerpt supports 'adults at increased risk' but does not enumerate or support a generalized list of 'other conditions' (1 INDICATIONS AND USAGE).
Rosuvastatin can be taken with or without food.
No provided label excerpt states a food effect or administration flexibility (available sections exclude food effect information).
Rosuvastatin should be taken at the same time each day.
No provided label excerpt instructs same-time daily dosing (available sections exclude this instruction).
The cholesterol-lowering effect of rosuvastatin develops over several weeks.
The provided excerpts include lipid reductions over 6-week study durations but do not explicitly state onset as 'over several weeks' (14 CLINICAL STUDIES).
Follow-up blood tests are used to check whether LDL-C is at target levels.
No provided label excerpt describes routine LDL-C target monitoring or 'target levels' follow-up testing (available sections provided do not include such language).
Follow-up blood tests are used to check whether triglycerides are at target levels (sometimes).
No provided label excerpt describes triglyceride target monitoring or conditional ('sometimes') target testing (available sections provided do not include such language).
Dose adjustments can be made based on response and tolerability.
The provided excerpts discuss study titration/dosing in specific trials/populations but do not provide a general label instruction that dose adjustments are made based on response and tolerability (available sections provided do not include this guidance).
Patients are advised to keep follow-up lab appointments as ordered by their prescriber.
No provided label excerpt contains this instruction about keeping follow-up lab appointments (17 PATIENT COUNSELING INFORMATION excerpt provided does not include it).
Contradictions
Important Omissions
Boxed warnings/contraindications/warnings-precautions content was not evaluated because the provided label excerpts in the prompt do not include those sections.
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Several claims are not supported by the provided label excerpts and could lead to inaccurate patient counseling or dosing/monitoring practices (food administration, same-time instruction, monitoring to 'target levels,' generalized dose-adjustment basis, and overbroad CV-prevention population framing).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple administration, monitoring/targets, dose-adjustment, and CV-prevention population statements are not supported by the provided label excerpts.
Suggested Improvement
Restrict claims to the provided label wording/excerpts (e.g., CV prevention: 'adults at increased risk for CV events' per indication) and remove or qualify unsupported guidance on food, same-time dosing, LDL/TG 'target' monitoring, and generalized dose adjustment criteria unless supported by the missing label sections.